AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28974061 — intervention group
Group type: EXPERIMENTAL
Intervention: WNJ SJOV
Number of subjects: 1781
Study 28974061 — intervention group
Group type: COMPARATOR
Intervention: WNJ oxygen
Number of subjects: 1781
Study 28974061 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula oxygen
Number of subjects: 1781
Study 26032442 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Number of subjects: 260
Study 26032442 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 260
Study 23712109 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-PTSD
Number of subjects: 74
Study 23712109 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment-as-usual wait list)
Number of subjects: 74
Study 21852403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Def (SIC without replacing the energy deficit)
Number of subjects: 12
Study 21852403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Bal (SIC with replacing the energy deficit)
Number of subjects: 12
Study 21852403 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study 19587124 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive feeding intervention (6-session educational program)
Number of subjects: 203
Study 19587124 — intervention group
Group type: COMPARATOR
Intervention: Informational control group
Number of subjects: 203
Study 18075400 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-Endorphin
Number of subjects: 40
Study 18075400 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 0.8 mg
Number of subjects: 40
Study 18075400 — intervention group
Group type: COMPARATOR
Intervention: Adenosine (various doses)
Number of subjects: 40
Study 15483563 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 17
Study 15483563 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 17
Study 11498727 — intervention group
Group type: EXPERIMENTAL
Intervention: B. monniera (300 mg)
Number of subjects: 0
Study 8761844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms beraprost sodium (BPS60 group)
Number of subjects: 164
Study 8761844 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms beraprost sodium (BPS120 group)
Number of subjects: 164
Study 8761844 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms beraprost sodium (BPS180 group)
Number of subjects: 164
Study 8761844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 8761844 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms beraprost sodium
Number of subjects: 164
Study 8761844 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 micrograms beraprost sodium
Number of subjects: 164
Study 1317294 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan
Number of subjects: 358
Study 1317294 — intervention group
Group type: COMPARATOR
Intervention: 900 mg oral aspirin plus 10 mg oral metoclopramide
Number of subjects: 358
Study 3933736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation
Number of subjects: 66
Study 3933736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31088418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced open-door policy with additional strategic and personnel support on intervention wards.
Number of subjects: 2
Study 31088418 — intervention group
Group type: COMPARATOR
Intervention: Control wards opened facultatively without the enhanced open-door policy.
Number of subjects: 2
Study 30101600 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved written materials (intervention group)
Number of subjects: 670
Study 27090149 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week vocal music therapy treatment group
Number of subjects: 55
Study 27090149 — intervention group
Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 55
Study 25099533 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal guided iSMI (GET.ON Stress)
Number of subjects: 0
Study 25099533 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided iSMI (GET.ON Stress)
Number of subjects: 0
Study 25099533 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (WLC)
Number of subjects: 0
Study 25099533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis from societal perspective
Number of subjects: 0
Study 25099533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis from employer's perspective
Number of subjects: 0
Study 21081251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20mg thrice daily in addition to bosentan
Number of subjects: 32
Study 19348535 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affective priming using verbal primes
Number of subjects: 0
Study 19348535 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affective priming using pictorial primes
Number of subjects: 0
Study 17469728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate 10 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Number of subjects: 70
Study 17469728 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate 20 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Number of subjects: 70
Study 15207886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimostil (57.2 mg total isoflavones)
Number of subjects: 252
Study 15207886 — intervention group
Group type: EXPERIMENTAL
Intervention: Promensil (82 mg total isoflavones)
Number of subjects: 252
Study 15207886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 15207886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimostil and Promensil
Number of subjects: 252
Study 15207886 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 252
Study 11699249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma linolenic acid containing products
Number of subjects: 47
Study 11699249 — intervention group
Group type: COMPARATOR
Intervention: Various herbal therapies
Number of subjects: 47
Study 9828735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (15 mg/kg every 8 hours for 7 days)
Number of subjects: 140
Study 9828735 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 140
Study 9828735 — intervention group
Group type: EXPERIMENTAL
Intervention: Necrotising enterocolitis (in both groups)
Number of subjects: 140
Study 1693088 — intervention group
Group type: EXPERIMENTAL
Intervention: Method WGS (spoken instructions included)
Number of subjects: 20
Study 1693088 — intervention group
Group type: EXPERIMENTAL
Intervention: Method WGSD (spoken instructions and video demonstration included)
Number of subjects: 20
Study 1693088 — intervention group
Group type: EXPERIMENTAL
Intervention: Method WG (graphics included)
Number of subjects: 20
Study 1693088 — intervention group
Group type: COMPARATOR
Intervention: Method W (written instructions only)
Number of subjects: 20
Study 1693088 — intervention group
Group type: EXPERIMENTAL
Intervention: Method WGSD (video demonstration included)
Number of subjects: 20
Study 387491 — intervention group
Group type: EXPERIMENTAL
Intervention: Finorgal
Number of subjects: 30
Study 387491 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 30
Study 387491 — intervention group
Group type: COMPARATOR
Intervention: Triclofos sodium
Number of subjects: 30
Study 387491 — intervention group
Group type: EXPERIMENTAL
Intervention: Finorgal, Nitrazepam, Triclofos sodium
Number of subjects: 30
Study 29997167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (intensive care with cooling of the body to 33.5°C for 72 hours)
Number of subjects: 130
Study 29997167 — intervention group
Group type: COMPARATOR
Intervention: Control (intensive care alone)
Number of subjects: 130
Study 29997167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 130
Study 29997167 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 27858219 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (measured by Patient Health Questionnaire and Mental Health Index of the SF-36)
Number of subjects: 241
Study 27858219 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing (measured by Coping Strategies Questionnaire)
Number of subjects: 241
Study 24947595 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA anodal stimulation to the left dorsolateral prefrontal cortex for 20 minutes on 10 consecutive days)
Number of subjects: 26
Study 24947595 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 26
Study 24947595 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study 22752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (GSE)
Number of subjects: 0
Study 22752876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21116598 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 4000 without electrolytes
Number of subjects: 38
Study 21116598 — intervention group
Group type: COMPARATOR
Intervention: Magnesium hydroxide
Number of subjects: 38
Study 19459773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone for 2 h
Number of subjects: 15
Study 16764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives initiated at 10 mm follicle diameter
Number of subjects: 45
Study 16764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives initiated at 14 mm follicle diameter
Number of subjects: 45
Study 16764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives initiated at 18 mm follicle diameter
Number of subjects: 45
Study 16764869 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 45
Study 15526045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 706
Study 15526045 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 706
Study 11724652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically nebulized distilled water (UNDW) 8 ml
Number of subjects: 10
Study 11724652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically nebulized distilled water (UNDW) 16 ml
Number of subjects: 10
Study 11724652 — intervention group
Group type: COMPARATOR
Intervention: Isotonic solution
Number of subjects: 10
Study 11724652 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-nitro-L-arginine methyl ester (L-NAME)
Number of subjects: 10
Study 11724652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically nebulized distilled water (UNDW) after L-NAME
Number of subjects: 10
Study 9129015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-specific idiotype vaccine (tumor Ig protein coupled to keyhole limpet hemocyanin and emulsified in an immunologic adjuvant)
Number of subjects: 41
Study 9129015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-specific idiotype vaccine
Number of subjects: 41
Study 7895178 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human parathyroid hormone (PTH 1-38) infusion for 24 hours in 14 healthy females
Number of subjects: 36
Study 7895178 — intervention group
Group type: COMPARATOR
Intervention: Primary hyperparathyroidism (HPT)
Number of subjects: 36
Study 3249838 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 32
Study 3249838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 32
Study 3249838 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Diazepam
Number of subjects: 32
Study 3249838 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Zopiclone
Number of subjects: 32
Study 31237948 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure (from 14 days before to 7 days after vaccination)
Number of subjects: 1174
Study 31237948 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed to antibiotics
Number of subjects: 1174
Study 29633247 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzene exposure during childhood above the 90th percentile
Number of subjects: 1989
Study 29633247 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher benzene exposure
Number of subjects: 1989
Study 28739134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 0.8 mg/kg
Number of subjects: 24
Study 28739134 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST (stress-induction)
Number of subjects: 24
Study 28739134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26697137 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long chain polyunsaturated fatty acids (n‐3 LC‐PUFA) enriched enteral formula (98 mg/d eicosapentaenoic acid and 46 mg/d docosahexaenoic acid)
Number of subjects: 55
Study 26697137 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long chain polyunsaturated fatty acids (n‐3 LC‐PUFA) enriched enteral formula
Number of subjects: 55
Study 26697137 — intervention group
Group type: COMPARATOR
Intervention: Reference enteral diet
Number of subjects: 55
Study 22652346 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psycho-education intervention about cognition
Number of subjects: 80
Study 22652346 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 20801941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day
Number of subjects: 192
Study 20801941 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ)
Number of subjects: 192
Study 19066678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 60
Study 19066678 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 60
Study 19066678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19066678 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 60
Study 19066678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 60
Study 15845566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) on days 1 and 8 plus docetaxel 50 mg/m(2) on day 8
Number of subjects: 59
Study 15845566 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended regimen (Gemcitabine 1000 mg/m(2) on days 1 and 8 plus docetaxel 50 mg/m(2) on day 8)
Number of subjects: 59
Study 12875145 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Heart School activities (intervention group)
Number of subjects: 184
Study 12875145 — intervention group
Group type: COMPARATOR
Intervention: Declined participation in Heart School activities (comparison group)
Number of subjects: 184
Study 10609423 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational therapy (FFT)
Number of subjects: 22
Study 10609423 — intervention group
Group type: COMPARATOR
Intervention: Crisis management with naturalistic follow-up (CMNF)
Number of subjects: 22
Study 8690106 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg once monthly plus 600 mg/d iron
Number of subjects: 0
Study 8690106 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 3.6 mg once monthly plus placebo iron
Number of subjects: 0
Study 8690106 — intervention group
Group type: COMPARATOR
Intervention: Iron alone (600 mg/d)
Number of subjects: 0
Study 1906962 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff Service
Number of subjects: 937
Study 1906962 — intervention group
Group type: COMPARATOR
Intervention: Resident Service
Number of subjects: 937
Study 6370482 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tablets
Number of subjects: 10
Study 6370482 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tablets
Number of subjects: 10
Study 6370482 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% suspension
Number of subjects: 10
Study 6370482 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 10
Study 30264179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the quadriceps muscle (850 nm, 5 J per diode)
Number of subjects: 14
Study 30264179 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 25575755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation training (comparing pairs of 2D or 3D objects and rotation games)
Number of subjects: 48
Study 25575755 — intervention group
Group type: COMPARATOR
Intervention: Active control (performing parallel non-spatial activities)
Number of subjects: 48
Study 25575755 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 48
Study 24124921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil (ILV) 10 mg weekly for 12 weeks
Number of subjects: 105
Study 24124921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil (ILV) 10 mg weekly for 12 weeks + oral antioxidants (one tablet once a day for 3 months)
Number of subjects: 105
Study 24124921 — intervention group
Group type: COMPARATOR
Intervention: Control group (ILV monotherapy)
Number of subjects: 105
Study 23045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Softened lighting and music
Number of subjects: 0
Study 23045865 — intervention group
Group type: COMPARATOR
Intervention: Standard lighting and music (implied control)
Number of subjects: 0
Study 20237064 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg beta-carotene
Number of subjects: 7
Study 20237064 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg beta-carotene
Number of subjects: 7
Study 17334775 — intervention group
Group type: COMPARATOR
Intervention: Placebo non-competitive (PNon)
Number of subjects: 10
Study 17334775 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol non-competitive (betaNon)
Number of subjects: 10
Study 17334775 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in simulated competition (PCom)
Number of subjects: 10
Study 17334775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol in simulated competition (betaCom)
Number of subjects: 10
Study 16365469 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity guideline implementation
Number of subjects: 3219
Study 16365469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity guideline implementation
Number of subjects: 3219
Study 16365469 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity guideline implementation
Number of subjects: 3219
Study 12409829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bentiromide test
Number of subjects: 18
Study 9475575 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 18
Study 9475575 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no phenylephrine)
Number of subjects: 18
Study 7624490 — intervention group
Group type: EXPERIMENTAL
Intervention: Butocamide hydrogen succinate (BAHS) 600 mg
Number of subjects: 12
Study 7624490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12
Study 7624490 — intervention group
Group type: EXPERIMENTAL
Intervention: BAHS 600 mg + Nitrazepam 5 mg
Number of subjects: 12
Study 7624490 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 12
Study 2196359 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.9 mg/kg/day)
Number of subjects: 12
Study 2196359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 359752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin G alone
Number of subjects: 127
Study 359752 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin G combined with hexachlorophene scrubbing
Number of subjects: 127
Study 359752 — intervention group
Group type: EXPERIMENTAL
Intervention: Children whose skin cultures grew Group A beta hemolytic streptococci
Number of subjects: 127
Study 359752 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with staphylococcus aureus as the only pathogen isolated
Number of subjects: 127
Study 359752 — intervention group
Group type: COMPARATOR
Intervention: Hexachlorophene scrubbing (regardless of pathogens isolated)
Number of subjects: 127
Study 30669618 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μM Epigallocatechin-3-gallate (EGCG)
Number of subjects: 0
Study 30669618 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μM Epigallocatechin-3-gallate (EGCG)
Number of subjects: 0
Study 30669618 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 30669618 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG treatment
Number of subjects: 0
Study 29129251 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg (or 30 mg for specific conditions)
Number of subjects: 2199
Study 29129251 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199
Study 29129251 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 29129251 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban and Enoxaparin-warfarin
Number of subjects: 2199
Study 23033246 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate (FENO‐S)
Number of subjects: 139
Study 23033246 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin plus placebo (PL‐S)
Number of subjects: 139
Study 22470031 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin, FOS and ALA enriched cookie
Number of subjects: 36
Study 22470031 — intervention group
Group type: COMPARATOR
Intervention: Control cookie
Number of subjects: 36
Study 19181980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged ankle-foot orthoses
Number of subjects: 15
Study 19181980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthoses
Number of subjects: 15
Study 19181980 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 15
Study 17144178 — intervention group
Group type: EXPERIMENTAL
Intervention: BiDil
Number of subjects: 0
Study 15000354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic WAD subjects
Number of subjects: 0
Study 15000354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0